ANGELICO, Mario
 Distribuzione geografica
Continente #
NA - Nord America 1.149
EU - Europa 337
AS - Asia 214
SA - Sud America 27
AF - Africa 6
Totale 1.733
Nazione #
US - Stati Uniti d'America 1.142
SE - Svezia 106
SG - Singapore 88
IN - India 62
FI - Finlandia 54
CN - Cina 53
IT - Italia 51
DE - Germania 40
UA - Ucraina 40
RU - Federazione Russa 14
BR - Brasile 13
IE - Irlanda 10
GB - Regno Unito 8
CA - Canada 7
AR - Argentina 5
VE - Venezuela 5
CO - Colombia 4
FR - Francia 4
CH - Svizzera 3
ID - Indonesia 3
IR - Iran 3
NL - Olanda 3
BG - Bulgaria 2
CI - Costa d'Avorio 2
TG - Togo 2
TR - Turchia 2
ZA - Sudafrica 2
JP - Giappone 1
NO - Norvegia 1
RO - Romania 1
TW - Taiwan 1
VN - Vietnam 1
Totale 1.733
Città #
Fairfield 210
Chandler 109
Woodbridge 94
Ashburn 78
Houston 73
Cambridge 70
Seattle 69
Singapore 58
Princeton 55
Wilmington 48
Beijing 39
Plano 35
Millbury 28
San Paolo di Civitate 27
Helsinki 23
Lawrence 22
Bremen 20
San Diego 18
Santa Clara 18
Jacksonville 17
Ann Arbor 16
Rome 15
Andover 11
Boston 11
Dearborn 11
Dublin 10
Falkenstein 7
Caracas 5
Federal 5
New York 4
Ottawa 4
Campinas 3
Falls Church 3
Hefei 3
Jakarta 3
Moscow 3
Southend 3
São Paulo 3
Abidjan 2
Bern 2
Boardman 2
Brasília 2
Buffalo 2
Bühl 2
Des Moines 2
Florence 2
Henderson 2
Ibagué 2
Istanbul 2
Johannesburg 2
Lomé 2
Marseille 2
Medellín 2
Milan 2
Norwalk 2
Paris 2
Phoenix 2
Portland 2
Porto Alegre 2
Sofia 2
São José do Rio Preto 2
Winnipeg 2
Yellow Springs 2
Augusta 1
Calgary 1
Changsha 1
Fuzhou 1
Guangzhou 1
Ho Chi Minh City 1
Jinan 1
Kilburn 1
Langfang 1
Leawood 1
London 1
Mannheim 1
Miaoli 1
Nanjing 1
Napoli 1
Nuremberg 1
Oslo 1
Palermo 1
Sacramento 1
San Jose 1
San Mateo 1
Tokyo 1
Trumbull 1
Washington 1
Wenzhou 1
Zanjan 1
Zurich 1
Totale 1.308
Nome #
Lack of reduction of serum alphafetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hcv-related cirrhosis 104
THU-117-Evaluation of risk factors associated with failure to a first-line NS5A-containing regimen in HCV-infected patients naive to direct acting antivirals: Particular focus on natural resistance 81
An improved gas-chromatographic method for the determination of sulfated and unsulfated bile acids in serum 73
A survey on mortality from non-variceal upper gastrointestinal bleeding: Is the emergency referral system adequate? 69
Impact of remnant vital tissue after locoregional treatment and liver transplant in hepatocellular cancer patients. A multicentre cohort study 68
Octopamine plasma levels and hepatic encephalopathy: a re-appraisal of the problem. 68
Octopamine and ammonia plasma levels in hepatic encephalopathy 67
The meaning of serum bile acid patterns. 66
Fasting and postprandial serum bile acids as a screening test for hepatocellular disease 65
Biliary sludge: a critical update. 62
A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. 62
Sulfated bile acids in serum, bile, and urine of cirrhotic patients before and after portacaval anastomosis. 62
Differences in serum bile acid composition between unoperated cirrhotic patients and patients with portacaval or mesocaval shunt 59
Influence of portacaval anastomosis on serum and biliary unsulfated bile acid composition in patients with liver cirrhosis. 59
High prevalence of metabolic syndrome and long-term survival after liver transplantation 56
Clinical trial: low plasma cholesterol and oxidative stress predict rapid virological response to standard therapy with peginterferon and ribavirin in HCV patients 55
Electronic outpatient referral system for liver transplant improves appropriateness and allows first visit triage 55
Serum cholesterol after portacaval shunting. 54
Structure of biliary phosphatidylcholine in cholesterol gallstone patients. 52
Drawbacks in the use of 23-nor-deoxycholic acid standards 51
Roman Liver Tx Allocation: Results at 48 months of an innovative regional allocationmodel based on MELDNa and Donor-to-Recipient Match 47
Most Helicobacter pylori infected patients have specific antibodies, and some also have H. pylori antigens and genes in the bile: is it a risk factor for gallstone formation ? 46
Ursodeoxycholic acid (Ursacol) in the dissolution of cholesterol gallstones. A comparison of three different dosages 43
Gallstones in Cystic Fibrosis: a critical reapprasail 40
Effect of low doses of ursodeoxycholic acid on biliary lipid composition in non obese gallstone patients 37
[Serum bile acids in congestive heart failure]. 34
Colesterolo HDL: prospettive nella prevenzione della cardiopatia ischemica 31
Prevalence of gallstones in patients with primary immunoglobulin deficiency: evidence for a lack of association. 31
Valutazione dell'encefalopatia epatica in 35 pazienti ipertesi portali operato con anastomosi porta cava o di by pass mesenterico cava 29
Effect of ursodeoxycholic acid on biliary lipid composition. A double blind study 28
Fasting and postprandial serum bile acid levels before and after remission of acute venous congestion of the liver 28
Retrospective survey on upper gastro-intestinal bleeding in lazio region: comparison between urgent endoscopy performed during working or out of working hours. 28
Sulfated and unsulfated serum bile acids in patients with cholestatic liver disease 25
Simple method for the simultaneous extraction and fractionation of biliary lipids by repartition between solvents 20
Results of a retrospective survey on upper gastro-intestinal bleeding in lazio region: large volume hospitals exhibit reduced mortality but an increased number of negative endoscopic examination 18
Presence of sulfated bile acids in ascitic fluid 17
Totale 1.790
Categoria #
all - tutte 5.193
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.193


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020252 0 0 0 0 0 43 48 46 38 31 36 10
2020/2021113 15 12 4 19 3 5 7 11 10 20 4 3
2021/2022370 7 24 29 11 41 16 4 46 22 27 64 79
2022/2023402 84 86 23 44 42 52 5 18 29 2 11 6
2023/2024142 15 28 6 10 6 8 1 24 0 23 7 14
2024/2025124 15 34 16 13 19 27 0 0 0 0 0 0
Totale 1.790